Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001: A report from the children's oncology group

W. L. Salzer, M. Devidas, W. L. Carroll, N. Winick, J. Pullen, S. P. Hunger, B. A. Camitta

Research output: Contribution to journalArticle

160 Citations (Scopus)

Abstract

From 1984 to 2001, the Pediatric Oncology Group (POG) conducted 12 acute lymphoblastic leukemia (ALL) studies. Ten-year event-free survival (EFS) for patients >12 months of age with B-precursor ALL on acute leukemia in children 14, 15 and 16 series were 66.7±1.2%, 68.1±1.4% and 73.2±2.1%, respectively. Intermediate dose methotrexate (ID MTX; 1 g/m2) improved outcomes for standard risk patients (10-year EFS 77.5±2.7% vs 66.3±3.1% for oral MTX). Neither MTX intensification (2.5 g/m2) nor addition of cytosine arabinoside/daunomycin/teniposide improved outcomes for higher risk patients. Intermediate dose mercaptopurine (1 g/m 2) failed to improve outcomes for either group. Ten-year EFS for patients with T-cell ALL, POG 8704 and 9404 were 49.1±3.1% and 72.2±4.7%, respectively. Intensive asparaginase (10-year EFS 61.8 vs 42.7%) and high-dose MTX (5 g/m 2) (10-year EFS 78.0 vs 65.8%) improved outcomes. There was a non-significant improvement in EFS for infants (10-year EFS 17.7±7.2-31.9±8.3%). Prognostic indicators for B-precursor ALL were age and WBC at diagnosis, gender, central nervous system disease, DNA index and cytogenetic abnormalities. Only gender was prognostic in T-cell ALL. In infants, WBC and MLL translocation were linked to inferior outcome.

Original languageEnglish (US)
Pages (from-to)355-370
Number of pages16
JournalLeukemia
Volume24
Issue number2
DOIs
StatePublished - Feb 2010

Fingerprint

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Disease-Free Survival
Pediatrics
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Teniposide
Asparaginase
6-Mercaptopurine
Daunorubicin
Central Nervous System Diseases
Cytarabine
Methotrexate
Chromosome Aberrations
Leukemia
DNA

Keywords

  • B-lineage ALL
  • Infant all
  • Outcome
  • Prognostic factors
  • T-lineage ALL

ASJC Scopus subject areas

  • Hematology
  • Cancer Research
  • Anesthesiology and Pain Medicine

Cite this

Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001 : A report from the children's oncology group. / Salzer, W. L.; Devidas, M.; Carroll, W. L.; Winick, N.; Pullen, J.; Hunger, S. P.; Camitta, B. A.

In: Leukemia, Vol. 24, No. 2, 02.2010, p. 355-370.

Research output: Contribution to journalArticle

Salzer, W. L. ; Devidas, M. ; Carroll, W. L. ; Winick, N. ; Pullen, J. ; Hunger, S. P. ; Camitta, B. A. / Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001 : A report from the children's oncology group. In: Leukemia. 2010 ; Vol. 24, No. 2. pp. 355-370.
@article{9183ab49654c488097a937f2499c0ebc,
title = "Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001: A report from the children's oncology group",
abstract = "From 1984 to 2001, the Pediatric Oncology Group (POG) conducted 12 acute lymphoblastic leukemia (ALL) studies. Ten-year event-free survival (EFS) for patients >12 months of age with B-precursor ALL on acute leukemia in children 14, 15 and 16 series were 66.7±1.2{\%}, 68.1±1.4{\%} and 73.2±2.1{\%}, respectively. Intermediate dose methotrexate (ID MTX; 1 g/m2) improved outcomes for standard risk patients (10-year EFS 77.5±2.7{\%} vs 66.3±3.1{\%} for oral MTX). Neither MTX intensification (2.5 g/m2) nor addition of cytosine arabinoside/daunomycin/teniposide improved outcomes for higher risk patients. Intermediate dose mercaptopurine (1 g/m 2) failed to improve outcomes for either group. Ten-year EFS for patients with T-cell ALL, POG 8704 and 9404 were 49.1±3.1{\%} and 72.2±4.7{\%}, respectively. Intensive asparaginase (10-year EFS 61.8 vs 42.7{\%}) and high-dose MTX (5 g/m 2) (10-year EFS 78.0 vs 65.8{\%}) improved outcomes. There was a non-significant improvement in EFS for infants (10-year EFS 17.7±7.2-31.9±8.3{\%}). Prognostic indicators for B-precursor ALL were age and WBC at diagnosis, gender, central nervous system disease, DNA index and cytogenetic abnormalities. Only gender was prognostic in T-cell ALL. In infants, WBC and MLL translocation were linked to inferior outcome.",
keywords = "B-lineage ALL, Infant all, Outcome, Prognostic factors, T-lineage ALL",
author = "Salzer, {W. L.} and M. Devidas and Carroll, {W. L.} and N. Winick and J. Pullen and Hunger, {S. P.} and Camitta, {B. A.}",
year = "2010",
month = "2",
doi = "10.1038/leu.2009.261",
language = "English (US)",
volume = "24",
pages = "355--370",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001

T2 - A report from the children's oncology group

AU - Salzer, W. L.

AU - Devidas, M.

AU - Carroll, W. L.

AU - Winick, N.

AU - Pullen, J.

AU - Hunger, S. P.

AU - Camitta, B. A.

PY - 2010/2

Y1 - 2010/2

N2 - From 1984 to 2001, the Pediatric Oncology Group (POG) conducted 12 acute lymphoblastic leukemia (ALL) studies. Ten-year event-free survival (EFS) for patients >12 months of age with B-precursor ALL on acute leukemia in children 14, 15 and 16 series were 66.7±1.2%, 68.1±1.4% and 73.2±2.1%, respectively. Intermediate dose methotrexate (ID MTX; 1 g/m2) improved outcomes for standard risk patients (10-year EFS 77.5±2.7% vs 66.3±3.1% for oral MTX). Neither MTX intensification (2.5 g/m2) nor addition of cytosine arabinoside/daunomycin/teniposide improved outcomes for higher risk patients. Intermediate dose mercaptopurine (1 g/m 2) failed to improve outcomes for either group. Ten-year EFS for patients with T-cell ALL, POG 8704 and 9404 were 49.1±3.1% and 72.2±4.7%, respectively. Intensive asparaginase (10-year EFS 61.8 vs 42.7%) and high-dose MTX (5 g/m 2) (10-year EFS 78.0 vs 65.8%) improved outcomes. There was a non-significant improvement in EFS for infants (10-year EFS 17.7±7.2-31.9±8.3%). Prognostic indicators for B-precursor ALL were age and WBC at diagnosis, gender, central nervous system disease, DNA index and cytogenetic abnormalities. Only gender was prognostic in T-cell ALL. In infants, WBC and MLL translocation were linked to inferior outcome.

AB - From 1984 to 2001, the Pediatric Oncology Group (POG) conducted 12 acute lymphoblastic leukemia (ALL) studies. Ten-year event-free survival (EFS) for patients >12 months of age with B-precursor ALL on acute leukemia in children 14, 15 and 16 series were 66.7±1.2%, 68.1±1.4% and 73.2±2.1%, respectively. Intermediate dose methotrexate (ID MTX; 1 g/m2) improved outcomes for standard risk patients (10-year EFS 77.5±2.7% vs 66.3±3.1% for oral MTX). Neither MTX intensification (2.5 g/m2) nor addition of cytosine arabinoside/daunomycin/teniposide improved outcomes for higher risk patients. Intermediate dose mercaptopurine (1 g/m 2) failed to improve outcomes for either group. Ten-year EFS for patients with T-cell ALL, POG 8704 and 9404 were 49.1±3.1% and 72.2±4.7%, respectively. Intensive asparaginase (10-year EFS 61.8 vs 42.7%) and high-dose MTX (5 g/m 2) (10-year EFS 78.0 vs 65.8%) improved outcomes. There was a non-significant improvement in EFS for infants (10-year EFS 17.7±7.2-31.9±8.3%). Prognostic indicators for B-precursor ALL were age and WBC at diagnosis, gender, central nervous system disease, DNA index and cytogenetic abnormalities. Only gender was prognostic in T-cell ALL. In infants, WBC and MLL translocation were linked to inferior outcome.

KW - B-lineage ALL

KW - Infant all

KW - Outcome

KW - Prognostic factors

KW - T-lineage ALL

UR - http://www.scopus.com/inward/record.url?scp=76749108960&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76749108960&partnerID=8YFLogxK

U2 - 10.1038/leu.2009.261

DO - 10.1038/leu.2009.261

M3 - Article

C2 - 20016527

AN - SCOPUS:76749108960

VL - 24

SP - 355

EP - 370

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 2

ER -